Vaxil Bio Ltd., of Toronto, said it R&D arm, Vaxil Biotherapeutics Israel and Rehovot, Israel-based Hadassah Medical Center have signed an agreement to work together on the company's immunotherapy platform, including its lead product, Immucin (MUC-1 peptide vaccine).